Vascular Calcification Clinical Trial
Official title:
Effect of Phosphorus on Valvular and Vascular Calcification in ESRD
Evaluation of the calcifying effect of phosphorus on vascular smooth muscle and detect the association between serum phosphorus and valvular and vascular calcification in end stage renal disease patients
Cardiovascular disease (CVD) is the main cause of death in patients with end stage renal
disease(ESRD). It is estimated that ESRD patients are 5 to 20 times more likely to die
because of cardiovascular causes than the general population .
Traditional cardiovascular risk factors do not completely explain higher mortality rates
among hemodialysis patients , and non traditional risk factors such as anemia, bone mineral
disease, hyperhomocysteinemia, inflammation, hypercoagulability, and left ventricular
hypertrophy (LVH) have been demonstrated to play an important role in this population.
A number of factors have been associated with progression of vascular calcification(VC) in
dialysis patients. Associations with age and duration of dialysis , diabetes mellitus
,abnormalities of mineral metabolism as well as use and dose of calcium based phosphate
binders have all been reported.
Hyperphosphatemia is a common problem among patients with ESRD. It is a highly prevalent
condition, as almost 40% of the U.S. hemodialysis population has a serum phosphate( PO4)
greater than 6.5 mg/dl . The overall mortality risk associated with serum phosphate( PO4)
above 6.5 mg/dl was 27% greater than that of patients with PO4 levels between 2.4 and 6.5
mg/dl. It is speculated that elevate PO4 may aggravate the effects of coronary
atherosclerosis through increased vascular calcification and smooth muscle proliferation . It
has also been suggested that myocardial calcification, a consequence of elevated PO4, may
alter microcirculatory hemodynamics through increased extravascular resistance and further
compromise myocardial perfusion. We, therefore, hypothesized that the increased mortality
risk associated with elevated PO4 levels was primarily related to cardiac rather than
non-cardiac causes of death.
A number of non-invasive imaging techniques are now available to detect and quantify vascular
calcification (VC). Indeed, plain x-rays of abdomen and extremities to identify macroscopic
calcifications of aorta and peripheral arteries;echocardiography for assessment of valvular
calcification;2D-ultrasound for calcification of carotid arteries, femoral arteries and aorta
and computed tomography technologies constitute the current armamentarium for detection and
quantification of cardiovascular calcification (VC) and its progression.
Electron beam computed tomography (EBCT) and multi-slice computed tomography (MSCT) represent
the gold standard for assessing the extent of coronary artery and aorta calcification.MSCT is
more widely available than EBCT
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03960437 -
The Effect of Etelcalcetide on CKD-MBD
|
Phase 2 | |
Recruiting |
NCT04983875 -
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Completed |
NCT02561299 -
Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study
|
N/A | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Active, not recruiting |
NCT02598635 -
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
|
Phase 4 | |
Completed |
NCT00183001 -
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
|
Phase 3 | |
Completed |
NCT04114695 -
Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease
|
||
Not yet recruiting |
NCT03169400 -
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
|
N/A | |
Completed |
NCT03314493 -
Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients
|
Phase 3 | |
Completed |
NCT03839732 -
Observer Variability in Scoring Abdominal Aortic Calcifications and Vertebral Morphometry
|
||
Completed |
NCT02610933 -
Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT02542319 -
Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00481364 -
Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT00694824 -
Vascular Calcification's Risk Factors in Haemodialysis Patients
|
||
Recruiting |
NCT01364688 -
Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT01675206 -
Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT03937349 -
Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
|
||
Completed |
NCT02719665 -
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
|
N/A | |
Recruiting |
NCT04753593 -
Use of Discarded Surgery Human Tissue Specimens for Basic Science Research
|